[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR119617A1 - Síntesis de un inhibidor de calicreína plasmática a escala de proceso - Google Patents

Síntesis de un inhibidor de calicreína plasmática a escala de proceso

Info

Publication number
AR119617A1
AR119617A1 ARP200102248A ARP200102248A AR119617A1 AR 119617 A1 AR119617 A1 AR 119617A1 AR P200102248 A ARP200102248 A AR P200102248A AR P200102248 A ARP200102248 A AR P200102248A AR 119617 A1 AR119617 A1 AR 119617A1
Authority
AR
Argentina
Prior art keywords
compound
kallicerein
inhibitor
synthesis
formula
Prior art date
Application number
ARP200102248A
Other languages
English (en)
Inventor
Yahya El-Kattan
Yarlagadda S Babu
Original Assignee
Biocryst Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc
Publication of AR119617A1 publication Critical patent/AR119617A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00—Preparation of carboxylic acid nitriles
    • C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Health & Medical Sciences (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)

Abstract

Métodos para preparar el Compuesto de fórmula (1), y sus sales. Los métodos de preparación del Compuesto de fórmula (1) son apropiados para usar a escala de proceso. Reivindicación 1: Un método, caracterizado porque comprende el paso de: combinar el compuesto C, o una sal del mismo, y el compuesto F, o una sal del mismo, en condiciones que permiten producir el compuesto D, o una sal del mismo, en donde: el compuesto C está representado por: la fórmula (2); el compuesto F está representado por: la fórmula (3); y el compuesto D está representado por: la fórmula (4).
ARP200102248A 2019-08-06 2020-08-06 Síntesis de un inhibidor de calicreína plasmática a escala de proceso AR119617A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962883396P 2019-08-06 2019-08-06

Publications (1)

Publication Number Publication Date
AR119617A1 true AR119617A1 (es) 2021-12-29

Family

ID=74504082

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200102248A AR119617A1 (es) 2019-08-06 2020-08-06 Síntesis de un inhibidor de calicreína plasmática a escala de proceso

Country Status (20)

Country Link
US (1) US20220289683A1 (es)
EP (1) EP4010320A4 (es)
JP (1) JP2022543419A (es)
KR (1) KR20220044276A (es)
CN (1) CN114206839A (es)
AR (1) AR119617A1 (es)
AU (1) AU2020324422A1 (es)
BR (1) BR112022002060A2 (es)
CA (1) CA3149176A1 (es)
CL (2) CL2022000264A1 (es)
CO (1) CO2022002392A2 (es)
CR (1) CR20220092A (es)
EC (1) ECSP22016209A (es)
IL (1) IL290113A (es)
JO (1) JOP20220021A1 (es)
MX (1) MX2022001608A (es)
PE (1) PE20221009A1 (es)
TW (1) TW202120481A (es)
UY (1) UY38826A (es)
WO (1) WO2021026182A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE052668T2 (hu) 2014-03-07 2021-05-28 Biocryst Pharm Inc Trifluorometillel szubsztituált pirazolok mint humán plazma kallikrein-gátlók
CN116375648A (zh) * 2023-03-22 2023-07-04 苏州农平科技发展有限公司 贝罗司他中间体的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
LU86084A1 (fr) 1985-09-20 1987-04-02 Faco Sa Apparei de massage electrique
US5102417A (en) 1985-11-07 1992-04-07 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4800882A (en) 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4886062A (en) 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
WO1990013332A1 (en) 1989-05-11 1990-11-15 Cedars-Sinai Medical Center Stent with sustained drug delivery
WO1991012779A1 (en) 1990-02-28 1991-09-05 Medtronic, Inc. Intralumenal drug eluting prosthesis
US5419760A (en) 1993-01-08 1995-05-30 Pdt Systems, Inc. Medicament dispensing stent for prevention of restenosis of a blood vessel
US5429634A (en) 1993-09-09 1995-07-04 Pdt Systems Biogenic implant for drug delivery and method
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
CA2454298A1 (en) * 2001-08-13 2003-02-27 Gary David Annis Substituted 1h-dihydropyrazoles, their preparation and use
US6770729B2 (en) 2002-09-30 2004-08-03 Medtronic Minimed, Inc. Polymer compositions containing bioactive agents and methods for their use
AU2009328584B2 (en) * 2008-12-18 2016-05-12 Bayer Cropscience Aktiengesellschaft Tetrazole substituted anthranilic acid amides as pesticides
HUE052668T2 (hu) 2014-03-07 2021-05-28 Biocryst Pharm Inc Trifluorometillel szubsztituált pirazolok mint humán plazma kallikrein-gátlók

Also Published As

Publication number Publication date
AU2020324422A1 (en) 2022-03-17
CO2022002392A2 (es) 2022-04-08
CL2022000264A1 (es) 2022-10-21
CA3149176A1 (en) 2021-02-11
JP2022543419A (ja) 2022-10-12
CL2023000942A1 (es) 2023-11-24
WO2021026182A1 (en) 2021-02-11
MX2022001608A (es) 2022-03-11
PE20221009A1 (es) 2022-06-15
JOP20220021A1 (ar) 2023-01-30
EP4010320A4 (en) 2023-08-16
ECSP22016209A (es) 2022-06-30
CN114206839A (zh) 2022-03-18
TW202120481A (zh) 2021-06-01
CR20220092A (es) 2022-06-03
UY38826A (es) 2021-02-26
BR112022002060A2 (pt) 2022-06-07
KR20220044276A (ko) 2022-04-07
IL290113A (en) 2022-03-01
EP4010320A1 (en) 2022-06-15
US20220289683A1 (en) 2022-09-15

Similar Documents

Publication Publication Date Title
AR114631A1 (es) Métodos e intermedios para preparar compuestos de piridina
ECSP22057865A (es) Inhibidores de formas mutantes de egfr
AR111304A1 (es) Métodos para sintetizar un inhibidor de mcl-1
CU20180152A7 (es) Pirimidin-2-ilamino-1h-pirazoles útiles como inhibidores de lrrk2
AR111495A1 (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak
CL2021002244A1 (es) Compuesto inhibidor de jak y uso del mismo
SV2016005229A (es) Inhibidores de syk
CO2020006523A2 (es) Compuestos moduladores de sting y métodos de elaboración y uso
AR119617A1 (es) Síntesis de un inhibidor de calicreína plasmática a escala de proceso
BR112018011788A2 (pt) formas sólidas de éster etílico de ácido (2r,4s)-5-(bifenil-4-il)-4-[(3-carboxipropionil)amino]-2-metil-pentanoico, seus sais e um método de preparação
CO2019011604A2 (es) Compuestos inhibidores de vmat2, composiciones y métodos relativos a los mismos
CO2021010930A2 (es) Hidroxipiridoxazepinas como activadores de nrf2
AR094852A1 (es) Oestra-1,3,5(10),16-tetraeno-3-carboxamidas
DOP2014000178A (es) Nuevos derivados de bencil sulfonamida útiles como inhibidores de mogat-2
PE20170212A1 (es) Composicion reactiva basada en bicarbonato de sodio y procedimiento para su produccion
CL2024001364A1 (es) Inhibidores de pi3k-alfa y métodos para su producción y uso
AR116951A1 (es) Sales cristalinas de un inhibidor de calicreína plasmática
CU20210006A7 (es) Derivados de fenil-n-quinolina y proceso para su preparación
CL2018003872A1 (es) Sales cristalinas del inhibidor de inmunoproteasoma de péptido epoxicetona.
MX2023000970A (es) Metodo de preparacion de aminofuranos.
NZ774813A (en) New process for the synthesis of piperazinyl-ethoxy-bromophenyl derivatives and their application in the production of compounds containing them
BR112022003171A2 (pt) Processo para a síntese de compostos de pirazolidinona
PE20141794A1 (es) N-(3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-metilalaninamida como inhibidor de fosfatidilinositol 3-quinasa para el tratamiento de neoplasias linfoproliferativas
CL2019000294A1 (es) Síntesis de (s)-2-amino-4-metil-1-((r)-2-metiloxirano-2-il)-pentan-1-ona y sales farmacéuticamente aceptables de la misma.
AR105400A1 (es) Inhibidores de jak1